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Abstract Eukaryotic initiation factor eIF2B catalyses a key
regulatory step in mRNA translation. eIF2B and total protein
synthesis are acutely activated by insulin, and this requires
phosphatidylinositol 3-kinase (PI 3-kinase). The O-subunit of
eIF2B is phosphorylated by glycogen synthase kinase-3 (GSK-3),
which is inactivated by insulin in a PI 3-kinase-dependent
manner. Here we identify the phosphorylation site in eIF2BO as
Ser540 and show that treatment of eIF2B with GSK-3 inhibits its
activity. Ser540 is phosphorylated in intact cells and undergoes
dephosphorylation in response to insulin. This is blocked by PI 3-
kinase inhibitors. Insulin-induced dephosphorylation of this
inhibitory site in eIF2B seems likely to be important in the
overall activation of translation by this hormone.
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1. Introduction
mRNA translation is an important control point in gene
expression in eukaryotic cells [1,2] and acutely regulated by
a variety of agents, including hormones, mitogens, growth
factors and stress conditions. Insulin acutely activates protein
synthesis in a range of mammalian cell types, including tissues
of major importance for whole body protein metabolism such
as skeletal muscle and fat cells. Considerable e¡orts have
therefore been made to identify the regulatory mechanisms
by which this occurs [3]. Recent data indicate that the activa-
tion of protein synthesis by insulin requires signalling path-
ways involving phosphatidylinositol 3-kinase (PI 3-kinase),
based on the use of inhibitors of PI 3-kinase (such as wort-
mannin) and of mutants of the insulin receptor substrate,
IRS-1 [4,5].
The primary e¡ect of insulin on protein synthesis is at the
level of translation initiation [1,2] although e¡ects on elonga-
tion have also been reported [6]. Translation initiation re-
quires a set of (eukaryotic) initiation factors (eIFs) which
are involved in the process of binding the ribosome to the
mRNA and locating the correct start codon (reviewed in
[7]). The initiator methionyl-tRNA (Met-tRNAi) is brought
to the ribosome by initiation factor eIF2 in a complex also
containing GTP, which is subsequently hydrolysed during the
initiation process. After each initiation event, the active GTP-
bound form of eIF2 must be regenerated from [eIF2.GDP] by
a nucleotide-exchange reaction mediated by eIF2B, a hetero-
pentameric protein which plays an important role in regulat-
ing mRNA translation [8]. Since eIF2 is required for every
initiation event, regulation of the activities of eIF2 and eIF2B
can modulate overall rates of translation initiation. Previous
studies have shown that insulin activates this step of trans-
lation initiation in skeletal muscle and other types of cells [9^
13]. Activation of eIF2B by insulin requires PI 3-kinase [13].
Here we show that glycogen synthase kinase-3 (GSK-3)
phosphorylates eIF2B at a conserved serine residue in its O-
subunit (Ser540) and provide evidence that this results in the
inactivation of eIF2B. GSK-3 itself is inactivated in response
to insulin, and other agents which stimulate protein synthesis,
in a PI 3-kinase-dependent manner [13^19]. We show that
Ser540 is phosphorylated in intact cells and that insulin brings
about its dephosphorylation through a PI 3-kinase-dependent
mechanism. These ¢ndings point to the operation of a novel
signalling pathway by which insulin can activate overall trans-
lation initiation.
2. Materials and methods
2.1. Chemicals and biochemicals
Chemicals and biochemicals were obtained respectively from BDH
(Poole, Dorset, UK) and Sigma Chemical Co. (Poole, Dorset, UK),
unless otherwise stated. eIF2 and eIF2B were prepared from rabbit
reticulocyte lysates [20]. GSK-3K and -L were generously provided by
Professor Philip Cohen (University of Dundee). The Drosophila me-
lanogaster homologue of GSK-3 was kindly provided by Drs Ken
Hughes and Jim Woodgett (Toronto, Canada). Casein kinases-1 and
-2 were from Promega (Madison, USA). Synthetic peptides were pre-
pared by Dr G. Bloomberg (University of Bristol, UK).
2.2. Cells
CHO.T cells were maintained as described previously [21]. Prior to
insulin treatment, cells were stepped down into medium lacking serum
for 24 h. Insulin (20 nM) was added for 10 min before extraction of
the cells. Where used, wortmannin (100 nM) or LY294002 (20 WM)
were added 30 min before the treatment with insulin.
2.3. Analysis of translation factor activity and phosphorylation
Measurement of eIF2B activity, the in vitro phosphorylation of
eIF2B and the phosphorylation of the eIF2B-based peptides were
performed as outlined earlier [20,22]. CNBr and proteinase diges-
tions, phosphoamino acid analysis, peptide mapping and tricine gel
electrophoresis were carried out as described [23]. Amino acid se-
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quence analysis and identi¢cation of the site in eIF2B phosphorylat-
ed by GSK-3 was performed by Dr D.C. Pappin (Imperial Cancer
Research Fund Laboratories, London) [24]. CHO.T cells were ex-
tracted and fractionated by MonoQ chromatography as described
[12].
2.4. PCR ampli¢cation of partial cDNAs for eIF2BO
Total RNA was isolated using Trizol reagent (Gibco BRL) follow-
ing the manufacturer’s directions. cDNA was prepared from each
RNA sample using AMV reverse transcriptase (Promega cDNA syn-
thesis kit). Oligonucleotides were designed using conserved regions of
the nucleotide sequences of rat, rabbit and human eIF2BO. These
primers (not shown) £ank the region encoding the site in rabbit eIF2-
BO which is phosphorylated by GSK-3. The corresponding regions of
Chinese hamster and mouse eIF2BO were ampli¢ed by PCR using
these primers. In each case a single product of the predicted size
was obtained. The ampli¢ed DNA was puri¢ed and sequenced di-
rectly using an ABI 373A DNA sequencer.
2.5. Antisera
An anti-phosphopeptide antibody was raised in rabbit against the
peptide AELDS(p)RAGSPLC (where S(p) denotes phosphoserine),
which corresponds to the site in eIF2B phosphorylated in vitro by
GSK-3, as described previously [25,26]. For immunisation, the peptide
was conjugated to keyhole limpet haemocyanin using the heterobi-
functional crosslinker sulpho-MBS (m-maleimidobenzoyl-N-hydroxy-
sulphosuccinimide ester).
3. Results and discussion
3.1. GSK-3 phosphorylates eIF2B at a conserved serine residue
in its O-subunit
As reported previously, puri¢ed eIF2B was readily phos-
phorylated by GSK-3L [27] (Fig. 1A), and this occurred ex-
clusively on the largest (O)-subunit. Fig. 1A shows that eIF2BO
is also phosphorylated by the other isoform of GSK-3 found
in mammalian cells (K) and by its homologue from D. mela-
nogaster, the product of the zeste-white or shaggy gene (re-
views [19,28]). The only radiolabelled phosphoamino acid de-
tected following treatment of puri¢ed eIF2B with highly
puri¢ed GSK-3 was phosphoserine (Fig. 1B); in a previous
study using less highly puri¢ed GSK-3 we also detected some
phosphothreonine [27], but this has not been observed in any
of our subsequent studies. The initial rate of phosphorylation
of eIF2BO by GSK-3 was rapid and comparable to that of
glycogen synthase (GS). However, the ¢nal stoichiometry of
phosphorylation was often low, typically being about 0.1 mol
P/mol eIF2BO, although it varied slightly between prepara-
tions of eIF2B (0.08^0.14). Singh et al. [29] recently reported
a very similar stoichiometry for the phosphorylation of eIF2B
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Fig. 1. GSK-3 phosphorylates Ser540 in eIF2BO. A: Phosphorylation of eIF2B by GSK-3K (lane 1), GSK-3L (lane 2) and Shaggy (lane 3). Puri-
¢ed eIF2B was phosphorylated in vitro using either the K or L isoenzyme of mammalian GSK-3 or the Drosophila homologue Shaggy. The ar-
row shows the position of eIF2BO. B: Phosphoamino acid analysis of eIF2B radiolabelled using puri¢ed GSK-3. The positions of inorganic
phosphate (Pi), P-Ser, P-Thr and the origin are indicated. C: Location of the site in eIF2B phosphorylated by GSK-3 using solid phase se-
quencing. CNBr fragments from puri¢ed rabbit eIF2B phosphorylated by GSK-3 were resolved by tricine gel electrophoresis and transferred to
a polyvinylidene di£uoride membrane (PVDF, Problott, Applied Biosystems). The site phosphorylated by GSK-3 was identi¢ed using a Milligen
L600 solid-phase sequencer. The stained protein band was covalently immobilised on the surface of the Problott membrane by treatment with
poly(allylamine) and 1,4-phenylenediisothiocyanate. Cycle fractions were split to deliver 50% to the HPLC for identi¢cation of phenylthiohy-
dantoin derivatives, the remainder being collected for Cerenkov counting. The results from this sequence analysis were compared with the pub-
lished amino acid sequence to identify the site as Ser540 of the O subunit.
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by GSK-3 (0.12 mol P/mol eIF2B). This combination of high
initial rate but low plateau stoichiometry is likely to re£ect a
particular feature of the substrate speci¢city of GSK-3. Phos-
phorylation of a target residue by GSK-3 often depends on
the prior phosphorylation of the protein at a nearby serine,
e.g. in GS [28,30]. Thus the maximal level of phosphorylation
by GSK-3 of a site for which it requires a priming phospho-
serine is limited by the level of phosphorylation of this ‘prim-
ing site’. Most proteins that we isolate from reticulocyte ly-
sates are almost entirely in their dephosphorylated states [31^
33]. Thus the low stoichiometry of phosphorylation of eIF2B
by GSK-3 may re£ect a similarly low level of phosphorylation
of a priming site in the puri¢ed factor.
To identify the residue(s) phosphorylated by GSK-3, eIF2-
BO was radiolabelled by GSK-3, subjected to CNBr digestion
and the resulting fragments were analysed by polyacrylamide
gel electrophoresis using the tricine gel system [34]. Autora-
diography revealed a single labelled CNBr fragment of appa-
rent Mr about 6500 which was then subjected to automated
Edman degradation and the release of radiolabel was moni-
tored at each cycle (Fig. 1C). Apart from a small amount
appearing in the ¢rst cycle (Asp), no radioactivity was re-
leased before cycle 7, the ¢rst cycle where a Ser was encoun-
tered. Release of radioactivity trailed into the next cycle (Arg),
but thereafter no further radioactivity was released and none
remained associated with the peptide after the end of the
sequencing run (which did not proceed as far as the C-termi-
nus of the peptide). The sequence data obtained here
(DSEELDSRAGSPQLDDI) correspond to a region towards
the C-terminus of eIF2BO [35], the Ser labelled by GSK-3
being Ser540.
This sequence contains a Ser at +4 relative to the residue
phosphorylated by GSK-3 which could act as a priming phos-
phorylation site. Our recent experiments employing synthetic
peptides based on the sequence around Ser540 in eIF2BO [36]
demonstrated that prior phosphorylation of the serine at +4 is
essential for the phosphorylation of the residue corresponding
to Ser540 by GSK-3. These data o¡er strong support to the
idea that phosphorylation of this site in eIF2BO itself also
requires such a priming phosphorylation event. Consistent
with this, prior treatment of puri¢ed eIF2B with protein phos-
phatase-1 reproducibly abolished its subsequent phosphoryla-
tion by GSK-3 (data not shown).
When these experiments were performed, sequence data for
eIF2BO were available for only one species (rabbit [37]), which
we used to design primers for PCR to amplify partial cDNAs
corresponding to this region of eIF2BO from four other spe-
cies (Table 1). In each case, serines are present at the positions
corresponding to both the phosphorylation site for GSK-3
(Ser540) and Ser544 (the potential priming site) of the rabbit
sequence. We have sought to identify which protein kinase
might phosphorylate Ser544 and thus act as a ‘priming kinase’,
and have tested a number of enzymes, including casein kin-
ases-1 and -2, which can phosphorylate eIF2BO [20,29] but
failed to enhance the phosphorylation of eIF2B by GSK-3,
and several proline-directed kinases (since Ser544 is followed
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Fig. 2. E¡ect of GSK-3 on eIF2B activity in cell extracts The e¡ect
of GSK-3 on the activity of eIF2B was determined in reticulocyte
lysates (A) and in extracts from control and insulin-treated CHO.T
cells (B). Cell lysates or extracts were incubated with ATP (0.2 mM)
and MgCl2 (2 mM) at 30‡C for 20 min, with or without GSK-3. A:
Experiment 1: Samples of reticulocyte lysate were treated with
GSK-3 (K or L isoform) for 20 min prior to measurement of eIF2B
activity. Experiment 2: Samples of reticulocyte lysate were treated
with GSK-3L, MAPKAPK-1 or GSK-3L preincubated with MAP-
KAPK-1 and then assayed for eIF2B activity. Control are samples
incubated without GSK-3. Similar results were obtained in six sepa-
rate experiments. B: Experiment 1: Samples of CHO.T cell extracts
from control or insulin-treated cells were incubated without or with
GSK-3 prior to assay of eIF2B activity. In experiment 2, eIF2B was
partially puri¢ed from extracts of control or insulin-treated CHO.T
cells using fast £ow S-Sepharose as described previously [12]. eIF2B
was eluted with bu¡er containing 0.4 M NaCl. The partially puri-
¢ed eIF2B was then treated with or without GSK-3 and assayed for
activity.
Table 1
Sequence around the GSK-3 phosphorylation site in eIF2BO from various mammalian species
DSEEPDSRGGSPQMDDIKVF Human U23028
DPEELDSRAGSPQLDDIRVF Rat U19516
DSEELDSRAGSPQLDDIKVF Rabbit U23037
DSEELDSRAVSPQSDDIKVF Hamster This work
DPEELDSRAGSPQLDDIRVF Mouse This work
The site phosphorylated by GSK-3 in the rabbit factor and the corresponding residue in the polypeptide from other species is shown bold. The
putative priming serine is underlined.
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by a proline) but none of them phosphorylated eIF2BO. Fur-
ther work is therefore needed to identify the putative priming
kinase.
3.2. GSK-3-mediated phosphorylation inhibits the activity of
eIF2B
Since GSK-3 only phosphorylated puri¢ed eIF2B to a low
stoichiometry, we considered it unlikely that phosphorylation
by GSK-3 would a¡ect its activity signi¢cantly, and this was
indeed the case (data not shown). We therefore examined the
e¡ect of GSK-3 on the activity of eIF2B in cell extracts, based
on the arguments that in cell extracts either Ser544 in eIF2BO
might already be more fully phosphorylated or the putative
‘priming kinase’ might be present, permitting a higher level of
GSK-3-mediated phosphorylation and thus giving rise to a
larger change in eIF2B activity. Preincubation of reticulocyte
lysates with GSK-3 (K or L) resulted in a marked fall in eIF2B
activity (to about 35^40% of the control value, Fig. 2A) rel-
ative to the activity in controls which were not incubated or
incubated without GSK-3. This e¡ect was abolished by pre-
incubation of the GSK-3 with MAPKAPK-1 (which inacti-
vates GSK-3 [38,39]), indicating that it is due to the activity of
GSK-3 (Fig. 2A).
We also examined the e¡ect of GSK-3 on the activity of
eIF2B in extracts from CHO.T cells and NIH.3T3 HIR cells.
Both cell types express the human insulin receptor, and insulin
activates eIF2B in both ([13] and our unpublished data). Pre-
incubation of CHO.T cell extracts with GSK-3L reduced
eIF2B activity substantially, and to a greater extent in extracts
from insulin-treated cells than controls. Indeed, after pretreat-
ment with GSK-3L, the activities of eIF2B in the control and
insulin-treated cell extracts were almost equal (Fig. 2B). The
change in activity was retained after partial puri¢cation of the
eIF2B by ion exchange (Fig. 2B), indicating that it re£ects
reduced intrinsic activity of the factor rather than altering
its binding to a loosely associated regulator. Similar data
were obtained using extracts of control and insulin-treated
NIH.3T3 HIR cells (data not shown).
In these experiments, the maximal extents of inactivation
observed were in the range 80^90%. The residual activity
might either represent failure to achieve 100% occupancy of
Ser540 or genuine basal activity of the phosphorylated factor.
Although we have an anti-phosphopeptide antiserum with
which we can assess the relative level of phosphorylation of
Ser540 (see below), this approach does NOT give absolute lev-
els of phosphorylation and direct correlations of % phospho-
rylation and % activity are not therefore possible.
3.3. Ser540 in eIF2BO is phosphorylated in vivo and undergoes
dephosphorylation in response to insulin
To study the phosphorylation of Ser540 in intact cells, we
raised an antibody against a phosphopeptide corresponding to
the sequence surrounding this serine (AELDS(p)RAGSPC,
the cysteine being added to facilitate coupling of the peptide
to the carrier). When used against a panel of peptides related
to this sequence, it reacted with peptides containing a phos-
phate at this site whether or not there was also a phosphate
group at Ser544 (Fig. 3A). Thus the antibody can react with
Ser540(P) irrespective of the phosphorylation state of Ser544. It
did not react with their non-phosphorylated counterparts
(Fig. 3A). The antibody also reacted with eIF2B puri¢ed
from rabbit reticulocytes (Fig. 3B^D) showing that Ser540 is
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Fig. 3. Development of an anti-phosphopeptide antibody recognising Ser540(P) in eIF2BO. A: Dot blot in which the antibody raised against the
peptide AELDS540(p)RAGSPC was tested for reactivity against a panel of peptides whose sequences are based on that around Ser540 in eIF2B:
(a) RRAAEELDSRAGSPQL; (b) SRAGS544(p)PQSDC; (c) AELDS540(p)RAGS544(p)PQSDC; (d) AELDS540(p)RAGSPC. B: Dot blot show-
ing reactivity of the anti-phosphopeptide antibody against puri¢ed rabbit reticulocyte eIF2B pretreated with GSK-3 for the times indicated. C:
Three di¡erent preparations of puri¢ed rabbit eIF2B (a^c) were analysed by dot blot using the anti-phosphopeptide antibody with (+) or with-
out (3) prior incubation with protein phosphatase-2A (PP-2A). D: Western blot (using the anti-phosphopeptide antibody) of puri¢ed reticulo-
cyte eIF2B either untreated (3) or preincubated with GSK-3L and ATP for 30 min (+). The position of eIF2BO is indicated.
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already partially phosphorylated in these preparations. The
strength of the signal increased markedly when the eIF2B
was pretreated with GSK-3 (Fig. 3B,D), demonstrating that
it re£ects the level of phosphorylation of Ser540. Conversely
treatment of the eIF2B with phosphatase 2A resulted in a
total loss of reactivity (Fig. 3C).
The anti-phospho-Ser540 antibody was then used to analyse
the level of phosphorylation of this site in eIF2B partially
puri¢ed from control or insulin-treated CHO.T cells. A clear
signal in the position of the O-subunit of eIF2B was obtained
showing that this site is indeed phosphorylated in intact cells
(Fig. 4A). Furthermore, the signal was substantially reduced
for eIF2B partially puri¢ed from insulin-treated cells as com-
pared to control cells. As expected, the signal was totally
abolished by treatment of these fractions with phosphatase
2A and increased by pretreatment with GSK-3 (Fig. 4A). In
particular, treatment with GSK-3 eliminated the di¡erence in
the strength of the signal for eIF2B from control and insulin-
treated cells. A selective inhibitor of PI 3-kinase, wortmannin,
blocked the ability of insulin to induce dephosphorylation of
Ser540 in eIF2B (Fig. 4B), consistent with the requirement for
PI 3-kinase for the inhibition of GSK-3. The strengths of the
signals were quantitated by densitometric analysis of the ECL
image. Insulin caused a drop in the signal seen with the anti-
phosphopeptide antiserum, and wortmannin completely pre-
vented this e¡ect (intensity of signal: control cells, 100%; in-
sulin-treated cells, 67 þ 4%; cells treated with insulin in the
presence of wortmannin, 110 þ 15%). Similar data were ob-
tained using another inhibitor of PI 3-kinase, LY294002.
The relatively small e¡ect of insulin on the phosphorylation
of this site is re£ected in the modest activation of eIF2B
caused by insulin in CHO.T cells (Fig. 2B; [13] : larger e¡ects
on eIF2B activity are seen in other cell types [12,22,40]).
4. Conclusions
These data demonstrate that eIF2B is phosphorylated in
vivo at the site which is labelled in vitro by GSK-3 (Ser540)
and that this inhibitory site undergoes dephosphorylation in
intact cells in response to insulin. The activation of protein
synthesis and of eIF2B by insulin, and the dephosphorylation
of Ser540, all appear to be dependent on PI 3-kinase. Taken
together, the data suggest that the activation of protein syn-
thesis by insulin may be mediated to a large extent through
the inactivation of GSK-3, and the consequent dephosphoryl-
ation and activation of eIF2B, which is required for overall
translation initiation.
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phosphopeptide antibody. The arrows show the position of eIF2BO.
Samples of fractions from control (C) or insulin-treated (I) cells
were also treated either with PP2A or GSK-3, as indicated, for 30
min at 30‡C prior to analysis. Similar data were obtained in three
separate experiments. B: Fractions from control cells (C) or cells
treated with insulin in the absence (I) or presence (IW) of wortman-
nin were subjected to SDS-PAGE and Western blotting using the
anti-phosphopeptide antiserum (upper blot) and the numbers below
each lane indicate the densitometric readings expressed as % control
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anti-eIF2BO monoclonal antibody, lower blot).
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